**Name of Journal: *World Journal of Methodology***

**ESPS Manuscript No: 16715**

**Column: Systematic Reviews**

**Early probiotics to prevent childhood metabolic syndrome: A systematic review**

Balasubramanian H *et al*. Probiotics and childhood metabolic syndrome

Haribalakrishna Balasubramanian, Sanjay Patole

**Haribalakrishna Balasubramanian, Sanjay Patole,** Department of Neonatal Paediatrics, KEM Hospital for Women, Subiaco, Perth WA 6008, Australia

**Sanjay Patole,** Centre for Neonatal Research and Education, University of Western Australia, Perth WA 6008, Australia

**Author contributions**: Patole S was responsible for concept and design of the study, initial literature search and revision of the manuscript; Balasubramanian H was responsible for acquisition and interpretation of data and wrote the first draft of the manuscript. Both authors approved the final version of the manuscript.

**Conflict-of-interest:** The authors declare no conflict of interest.

**Data sharing:** Technical appendix, statistical code, and dataset available from the corresponding author Prof. Sanjay Patole at olof.skoldenberg@ki.se

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to**: **Sanjay Patole, Professor,** Department of Neonatal Paediatrics, KEM Hospital for Women, 374 Bagot Road, Subiaco, Perth WA 6008, Australia. [sanjay.patole@health.wa.gov.au](mailto:sven.schulzke@health.wa.gov.au%0CAbstract)

**Telephone:** +61-8-93401260

**Received:** January 27, 2015

**Peer-review started:** January 28, 2015

**First decision:** March 6, 2015

**Revised:** April 5, 2015

**Accepted:** June 18, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To conduct a systematic review of studies on early probiotic supplementation to prevent childhood metabolic syndrome.

**METHODS:** Using the Cochrane systematic review strategy we searched PubMed, EMBASE, CENTRAL, CINAHL, and the conference proceedings of the Pediatric American Society meetings and trial registries in December 2014. Randomised controlled trials (RCTs) and non RCTs of probiotic supplementation to the mother and/or infant for a minimum duration of 4 weeks were selected. Of these, studies that reported on metabolic syndrome or its components (obesity, raised blood pressure, hyperglycemia, dyslipidemia) in children between 2-19 years were to be eligible for inclusion in the review. Risk of bias in selected RCTs and quality assessment of non-RCT studies were to be assessed by the Cochrane risk of bias assessment table and New Castle Ottawa scale.

**RESULTS:** There were no studies on early probiotic administration for prevention of childhood metabolic syndrome. Follow up studies oftwo placebo controlled RCTs (*n* = 233) reported on the effects of early probiotics on one or more components of metabolic syndrome in children aged 2-19 years. Meta-analysis of those two studies could not be performed due to differences in the patient population, type of outcomes studied and the timing of their assessment. Assessment of childhood metabolic outcomes was not the primary objective of these studies. The first study that assessed the effects of prenatal and postnatal supplementation of *Lactobacillus rhamnosus  GG* on body mass index till 10 years, did not report a significant benefit. In the second study, *Lactobacillus paracasei* 19 was supplemented to healthy term infants from 4-13 mo. No significant effect on body mass index, body composition or metabolic markers was detected.

**CONCLUSION:** Current evidence on early probiotic administration to prevent childhood metabolic syndrome is inadequate. Gaps in knowledge need to be addressed before large RCTs can be planned.

**Key words**: Probiotic; Infant; Perinatal; Metabolic syndrome; Obesity; Children

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Metabolic syndrome is a state of dysregulated glucose and lipid metabolism. The global health burden due to increasing prevalence of metabolic syndrome in children and adolescents, warrants urgent preventive interventions. Altered gut microbiota has been implicated in the pathogenesis of metabolic syndrome. The role of maternal and/or infant probiotic supplementation in improving metabolic health of the offspring is being researched. We provide a systematic review of this evidence. Gaps in the knowledge and issues regarding selection of patient population, probiotic intervention and outcomes for future trials have been discussed.

Balasubramanian H*,* Patole S. Early probiotics to prevent childhood metabolic syndrome: A systematic review. *World J Methodol* 2015; In press

**INTRODUCTION**

Metabolic syndrome (MS) is defined to include an array of risk factors that increase the chances of Cardio-vascular morbidity and type 2 diabetes in an individual. The World Health Organisation (WHO) in 1998, defined MS to comprise of insulin resistance in the presence of any two of the risk factors - obesity, hypertension, high triglyceride level, reduced high-density lipoprotein cholesterol level, or micro albuminuria[1]. Since then, various definitions for MS have been proposed. MS is increasingly being recognised in children. The diagnostic criteria for MS have been adapted for children and adolescents by the WHO, National Cholesterol Education Program, International Diabetes Federation and I Guidelines for prevention of atherosclerosis in childhood and adolescence (IGPAIA)[1-4]. There are more than ten different clinical definitions for childhood metabolic syndrome (CMS)[5]. Additionally, there are no unifying criteria that are representative of ethnically diverse groups. The age of onset of CMS is also unclear. A systematic review of 36 epidemiological studies analysing the prevalence of MS in children aged 2-19 years, reported a prevalence ranging from 1.2%-22.6% with rates up to 60% in overweight and obese children[6]. A recent systematic review has reported a mean overall prevalence of CMS as 3.3% (range: 0%-19.2%)[7]. The prevalence was higher in overweight [11.9% (2.8%-29.3%)] and obese [29.2% (10%-66%)] children. It was also higher among males and older children. Higher prevalence has been reported in the Middle East and the United States compared to Europe and the Far East. The variations in the definition of MS, ethnicity, age and nutritional status of the study population may explain the wide range of prevalence reported in these studies. To our knowledge, there is no data available on the health burden of CMS. Follow up of the Framingham Heart study cohort has revealed that the combination of central obesity, hypertension and hyperglycemia led to 2.36 times increase in the incidence of cardiovascular events and three-fold increase in mortality among adults[8]. MS results in a seven fold increase in the risk of type 2 diabetes[9].

Obesity is considered the most important component of CMS. Data from the National Centre of health Statistics, United States reveal that prevalence of obesity has doubled in children and quadrupled in adolescents in the past 30 years[10]. Increased prevalence of CMS is a direct result of the increasing trends of childhood obesity. Cost of illness studies from the United States, Australia, Germany have confirmed that health care utilisation by children with obesity, is significantly higher than their normal weight counterparts[11]. The annual medical expenditure due to childhood obesity in the United States is approximately 14 billion United States dollar and the projected costs for the next 30 years due to currently prevailing trends of adolescent obesity would be 45 billion USD[12,13]. Thus CMS has the potential to be a major public health concern to both the developed and developing countries[14].

***Pathogenesis of MS***

Pathogenesis of MS is complex and involves insulin resistance, lipid partitioning, hepatic steatosis, free radical injury and hormonal changes (leptin, adiponectin, resistin)[15-17].

***Role of gut microbiota***

Numerous reviews have indicated the role of altered gut microbiota in the pathogenesis of MS[18-20]. Gut microbiota (*e.g.,* *bacteroides*) can mediate energy harvest from diet resulting in obesity and type 2 diabetes[21]. Increased level of inflammatory markers (Lipopolysaccharides, TGF-β) by gram negative bacteria in the gut can increase gut permeability and oxidant injury and thereby affect the metabolic health[22]. The *firmicutes: bacteroides* ratio in the gut flora was significantly reduced in children with type 1 diabetes as compared to healthy children[23]. Obesity and excessive weight gain during pregnancy was associated with aberrations in the maternal gut microbiota[24]. Collado et al have reported lower stool bifidobacterial counts and reduced microbial diversity in infants born to obese mothers[25]. Follow up of that cohort revealed an increased risk of obesity at seven years of age[26]. It was suggested that early infancy gut microbial alteration could influence metabolic health of children and adolescents. Gut microbiota is also more amenable to modulation, prior to the establishment of adult type microbiota; i.e. in the first two years of life[27]. Hence, it could be hypothesised that interventions modulating gut microbiota in early infancy can potentially reduce the risk of CMS.

***Role of probiotics in prevention of MS***

Probiotics are ‘live micro-organisms which when administered in adequate amounts confer a specific health benefit on the host’. Probiotics have been shown to decrease body weight gain, adipose tissue mass, leptin and cholesterol levels. Diet induced hyperglycemia and hyperinsulinemia was controlled by probiotic supplementation. However, majority of the clinical evidence is from adult and animal studies[28-30]. The potential of probiotics in improving metabolic outcomes in children has been studied by maternal and/or early infant supplementation. The pathways for the potential benefits are direct modulation of the infant gut flora through breast milk or placenta and regulation of risk factors such as maternal hyperglycemia and obesity[31-34].

Given the significance of the health issue and the potential of probiotics as an intervention, we aimed to conduct a systematic review of studies reporting on probiotic supplementation to prevent CMS.

**MATERIALS AND METHODS**

***Study selection criteria***

The studyselection criteriais described as follows:(1) Studies: Randomized controlled trials (RCTs) and non-RCT studies; (2) Participants: Pregnant women and/or infants that received probiotic supplementation for at least 4 wk; (3) Intervention*:* Probiotic supplement of any strain, dose and form with or without prebiotic oligosaccharide for a duration of at least 4 wk; (4) Control*:* Standard treatment but no probiotics or placebo; and (5*)* Outcomemeasures*:* We broadly defined our outcome measures to account for variations in age, gender and ethnicity based cut offs for individual risk factors of CMS. To be included in this review, the studies should have assessed at least one of the following four components of MS - obesity, raised blood pressure, dyslipidemia (hypertriglyceridemia or low HDL cholesterol), hyperglycemia in children between 2-19 years. The outcome equivalents for each of the components are described as follows: (1) Obesity: BMI, waist circumference; (2) Hyperglycemia: Fasting plasma glucose, insulin levels, insulin resistance (assessed by HOMA IR), insulin sensitivity, fasting plasma glucose; (3) Dyslipidemia:Plasma lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol/HDL); and (4) Hypertension: Systolic blood pressure and /or diastolic blood pressure.

We followed the standard Cochrane methodology and the PRISMA (preferred reporting items for systematic reviews and meta-analysis), for conducting and reporting RCTs in this systematic review[35]. We followed the MOOSE guidelines (Meta-analysis of observational studies in epidemiology) for conducting and reporting outcomes of non-RCTs in this systematic review[36].

***Literature search***

We searched the Cochrane central register of controlled trials (CENTRAL) (http://www.cochrane.org/cochrane/hbook.htm), MEDLINE *via* PubMed (http://www.ncbi.nlm.nih.gov/Pubmed), EMBASE (http://www.embase.com) and annual conference proceedings of the Pediatric Academic Societies (www.pas-meeting.org)/ in December 2014. PubMed was searched using two search strategies: (1) *S*tudies of probiotics related to the components of metabolic syndrome using the MeSH keywords “insulin resistance” OR “ insulin sensitivity” OR “hyperglycemia” OR “type 2 diabetes mellitus” OR “obesity” OR “ overweight” OR “adipose tissue” OR “dyslipidemia” OR “ body composition” OR “bodyweights and measures” OR “hypertension” OR “blood pressure” AND “probiotics”; and (2) Studies of probiotic supplementation in pregnant women and infants using the MeSH keywords “infant” OR “infant, newborn” OR “pregnancy” AND “probiotics”.

For both searches, the MeSH word “probiotics” was replaced by *lactobacillus*, *bifidobacterium* and *saccharomyces* and citations were retrieved. We combined both the search strategies to retrieve studies of probiotics in pregnant women and infants that assessed one or more components of metabolic syndrome as defined for this review. The results of the database search are shown in a flow diagram (Figure 1).

No restrictions were applied on study design or language. Animal studies and studies involving patients > 19 years were excluded. References of the obtained studies were also reviewed to identify additional studies. The international trial registry (www.clinicaltrials.gov) and Australian Clinical Trials Registry (www.anzctr.org.au)were checked for ongoing/registered trials in this area.

***Data collection and analysis***

**Selection of studies:** HB and SP independently assessed for inclusion all the potential studies identified as a result of the search strategy. Any disagreements about study selection were resolved by discussion.

**Data extraction and management:** Both the authors independently completed a pre specified data extraction form for all included studies. Any disagreements in the extracted data were resolved through discussion.

**Assessment of risk of bias in included studies:** Risk of bias (ROB) in selected RCTs and quality assessment of non-RCT studies were assessed by the Cochrane ROB assessment table and the New Castle Ottawa scale[37,38]. Both the authors separately assessed each study. Additional information from the trial authors was requested to clarify methodology as necessary. Any disagreement was resolved by discussion.

**RESULTS**

Initial broad search yielded 278 citations. We could not find any study on the effects of probiotic administration on CMS. However, we retrieved two RCTs (*n* = 233) reporting on the effects of early probiotics on one or more components of MS in children aged 2-19 years[39,40] (Figure 1). Meta-analysis of these 2 studies could not be performed due to differences in the patient population, type of outcomes and the timing of their assessment. Hence we decided to conduct a narrative synthesis.

***Luoto 2010***

This was a follow up study of a double blinded RCT involving 159 mothers with family history of atopic eczema, allergic rhinitis or asthma. They were randomized to receive probiotics (*n* = 77) or placebo (*n* = 82). The intervention group received 1 x 1010 cfu/d of *Lactobacillus rhamnosus GG* for 4 wk before expected delivery and extending for 6 months postnatally to the mother/infant.

Frequency of atopic eczema in their children till 2 years of age was the primary end point of the study. The BMI and frequency of overweight and obesity was assessed in 113 children (Probiotic: 59, Placebo: 54) at 2, 4, 7, and 10 years of age. Obesity and overweight was assessed in both groups using the international obesity task force criteria. There was no significant difference in the adjusted mean BMI at any age between the 2 groups. Among the children that were overweight at 10 years, (Probiotic: 13, Placebo: 12), there was tendency towards lower mean BMI at 4 years in the probiotic group (*P* = 0.063, ANOVA for repeated measures.)

**Videhult 2014**

This was the follow up study of a RCT involving 179 vaginally delivered term infants with birth weight > 2500 g. These infants were fed cereals with or without probiotic (*Lactobacillus paracasei ssp F19* - 1 x 108 cfu) between 4-13 mo. The outcomes of interest were the number of days with infections and antibiotic prescriptions before and after the second and third doses (5.5 and 12 mo) of DTaP vaccine. A total of 120/179 children were assessed at 8-9 years for the following outcomes- BMI Z score, sagittal abdominal diameter, body composition (fat free mass, fat mass index, truncal fat %, android or gynoid fat %), plasma lipids, insulin, glucose and transaminases. No significant differences in body composition, growth and metabolic markers were noted in the two groups at 8-9 years of age.

Results of the ROB assessment are reported in Table 1.

**DISCUSSION**

Our systematic review identified two RCTs (*n* = 233) studying the effects of early probiotic supplementation on metabolic health in children. Meta-analysis of these 2 studies could not be performed due to differences in the patient population, type of outcomes studied and the timing of their assessment. The current evidence on the administration of probiotics to the mother or infant to prevent CMS is thus inadequate.

To our knowledge this is the first systematic review assessing the role of early probiotic supplementation in the prevention of CMS. Small number and sample size of the included studies was the main limitation of this systematic review. Included studies were not designed to study metabolic outcomes in children and had follow up losses of up to 30%. Considering the global burden of CMS and the metabolic benefits of probiotics in adults and animal models it is important to assess this intervention in large RCTs. Few issues need to be discussed with regards to the patient population, probiotic intervention and outcome assessment in such trials.

Selection of the infant population for such trials is crucial as the current evidence on benefits of probiotics with regards to CMS related outcomes is based on healthy term infants. Preterm infants and those with IUGR are at high risk for MS due to catch up growth and reduction in insulin sensitivity[41,42]. Infants of diabetic mothers are also at higher risk of MS[43]. Factors that put these infants at high risk of early infancy gut microbial aberrations include increased risk of caesarean delivery, prolonged hospital stay, decreased maternal contact, perinatal and/or postnatal antibiotic exposure, delayed enteral feeding, need for tube feeds, formula feeding and suboptimal nutrition[44]. Hence research should focus on these high risk infant groups, and maternal population, especially obese and diabetic mothers. Comprehensive assessment of gut flora and immunological profile would also be essential as they relate to the mechanisms/pathways of benefit of probiotic supplementation. Considering that the effects of probiotics are strain specific and host specific, selection of probiotics is an important issue. A comparative meta-analysis by Million et al has shown that *Lactobacillus acidophilus* administration resulted in significant weight gain in humans and in animals and *Lactobacillus gasseri* was associated with weight loss both in obese humans and in animals[45]. The same authors have also reported that obesity-associated gut microbiota is rich in *Lactobacillus reuteri* and depleted in *Bifidobacterium animalis* and *Methanobrevibacter smithii*[46]. Assessment of the effects of probiotics on body composition is helpful considering the nutritional benefits of probiotics[47,48]. Assessment of optimal timing and duration of intervention are also important issues in the RCTs of early probiotic supplementation for preventing CMS. Rinne et al have demonstrated that probiotic administration during the last 6 months of pregnancy and first 6 months postpartum did not influence long term (2 years) composition of the infant gut flora[49]. Perinatal metabolic programming and immune mediated effects on the infant gut flora by the administration of probiotic could explain the pathway of benefit[50]. Controlling for confounders (*e.g.,* dietary and lifestyle changes), assuring compliance during the prolonged period of supplementation, and monitoring for complications will be necessary[51-53]. Currently there are no universally accepted criteria for defining CMS or its components[54]. Selection of primary outcomes representative of some or all components of MS would be essential. Since the minimum age cut off described for CMS is unclear, standardisation of surrogate end points will be essential. Currently there are no studies showing a causal relation between MS and gut microbiota. Moreover, the risk factors for MS differ with age. Prematurity, low and high birth weight, rapid catch up growth, maternal undernutrition, maternal obesity and diabetes are potential risk factors for the components of CMS. This highlights the necessity to test early interventions (perinatal, early postnatal) for preventing CMS

In summary, current evidence is insufficient to assess the effects of probiotics in reducing the risk of MS in children and adolescents. Considering the global health burden of CMS and the potential role of a low cost intervention such as probiotic supplementation, clinical and epidemiological studies are urgently required in this field. Better understanding of the pathogenesis and population specific cut offs of the various components of CMS is required before high quality randomised trials can be undertaken to address this important issue.

**COMMENTS**

***Background***

Metabolic syndrome in children and adolescents is defined to include central obesity,hyperglycemia,high blood pressure and dyslipidemia. Probiotics have shown to reduce adipose tissue, glucose and triglyceride levels in animal models, but evidence in children and adolescents is insufficient.

***Research frontiers***

Observational studies have shown that altered gut flora in infancy is associated with obesity in childhood .Altered gut flora has also been noted in children with type 1 diabetes. Whether modulation of gut flora in early infancy by probiotic supplementation would decrease the risk of childhood obesity and glucose intolerance is unclear.

***Innovations and breakthroughs***

Evidence from a clinical trial suggests that perinatal probiotic interventions may decrease the risk of gestational diabetes and central obesity. A prospective study of perinatal probiotic supplementation in early infancy has shown to reduce the risk of excessive weight gain in obese children. However, data on childhood metabolic outcomes is limited. Currently there is insufficient evidence to support the role of early probiotics in CMS.

***Applications***

To date, there is no systematic review on early interventions to prevent childhood metabolic syndrome. Given the magnitude of the problem, we analysed the potential role of probiotic exposure in early life for prevention of childhood metabolic syndrome or its components. The cause - effect relationship of altered gut flora vs childhood metabolic syndrome needs to be studied. High quality RCTs analysing all components of Childhood MS are required.

***Peer-review***

Definitely this is an interesting topic and is properly argued by the authors. Unfortunately they could not present a meta-analysis because of the data available in the literature. However, it is important to publish this work to emphasize the urgent need for this kind of research.

**REFERENCES**

1 **World Health Organisation.** Definition, diagnosis and classification of diabetes mellitus and its complications: Report of WHO a Consultation. Part 1. Geneva: World Health Organization, 1999

2 **Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.** Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]

3 **Back Giuliano Ide C**, Caramelli B, Pellanda L, Duncan B, Mattos S, Fonseca FH. [I guidelines of prevention of atherosclerosis in childhood and adolescence]. *Arq Bras Cardiol* 2005; **85** Suppl 6: 4-36 [PMID: 16597097]

4 **Zimmet P**, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. The metabolic syndrome in children and adolescents - an IDF consensus report. *Pediatr Diabetes* 2007; **8**: 299-306 [PMID: 17850473 DOI: 10.1111/j.1399-5448.2007.00271.x]

5 **Steinberger J**, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, Mietus-Snyder ML. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. *Circulation* 2009; **119**: 628-647 [PMID: 19139390 DOI: 10.1161/circulationaha.108.191394]

6 **Tailor AM**, Peeters PH, Norat T, Vineis P, Romaguera D. An update on the prevalence of the metabolic syndrome in children and adolescents. *Int J Pediatr Obes* 2010; **5**: 202-213 [PMID: 19878092 DOI: 10.3109/17477160903281079]

7 **Friend A**, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. *Metab Syndr Relat Disord* 2013; **11**: 71-80 [PMID: 23249214 DOI: 10.1089/met.2012.0122]

8 **Franco OH**, Massaro JM, Civil J, Cobain MR, O'Malley B, D'Agostino RB. Trajectories of entering the metabolic syndrome: the framingham heart study. *Circulation* 2009; **120**: 1943-1950 [PMID: 19884471 DOI: 10.1161/circulationaha.109.855817]

9 **Alberti KG**, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. *Lancet* 2005; **366**: 1059-1062 [PMID: 16182882 DOI: 10.1016/s0140-6736(05)67402-8]

10 **National Center for Health Statistics.** Health, United States, 2011: With Special Features on Socioeconomic Status and Health. Hyattsville, MD: U.S. Department of Health and Human Services, 2012

11 **John J**, Wolfenstetter SB, Wenig CM. An economic perspective on childhood obesity: recent findings on cost of illness and cost effectiveness of interventions. *Nutrition* 2012; **28**: 829-839 [PMID: 22452837 DOI: 10.1016/j.nut.2011.11.016]

12 **Trasande L**, Chatterjee S. The impact of obesity on health service utilization and costs in childhood. *Obesity* (Silver Spring) 2009; **17**: 1749-1754 [PMID: 19300433 DOI: 10.1038/oby.2009.67]

13 **Lightwood J**, Bibbins-Domingo K, Coxson P, Wang YC, Williams L, Goldman L. Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model. *Am J Public Health* 2009; **99**: 2230-2237 [PMID: 19833999 DOI: 10.2105/ajph.2008.152595]

14 **Kelishadi R**. Childhood overweight, obesity, and the metabolic syndrome in developing countries. *Epidemiol Rev* 2007; **29**: 62-76 [PMID: 17478440 DOI: 10.1093/epirev/mxm003]

15 **D'Adamo E**, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. *Curr Probl Pediatr Adolesc Health Care* 2013; **43**: 114-123 [PMID: 23582593 DOI: 10.1016/j.cppeds.2013.02.004]

16 **Palmieri VO**, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. *J Nutr* 2006; **136**: 3022-3026 [PMID: 17116714]

17 **Embleton ND**. Early nutrition and later outcomes in preterm infants. *World Rev Nutr Diet* 2013; **106**: 26-32 [PMID: 23428677 DOI: 10.1159/000342553]

18 **Sanchez M**, Panahi S, Tremblay A. Childhood obesity: a role for gut microbiota? *Int J Environ Res Public Health* 2015; **12**: 162-175 [PMID: 25546278 DOI: 10.3390/ijerph120100162]

19 **Zhao L**. The gut microbiota and obesity: from correlation to causality. *Nat Rev Microbiol* 2013; **11**: 639-647 [PMID: 23912213 DOI: 10.1038/nrmicro3089]

20 **Tsai YT**, Cheng PC, Pan TM. Anti-obesity effects of gut microbiota are associated with lactic acid bacteria. *Appl Microbiol Biotechnol* 2014; **98**: 1-10 [PMID: 24232731 DOI: 10.1007/s00253-013-5346-3]

21 **Musso G**, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? *Diabetes Care* 2010; **33**: 2277-2284 [PMID: 20876708 DOI: 10.2337/dc10-0556]

22 **Cani PD**, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. *Gut Microbes* 2012; **3**: 279-288 [PMID: 22572877 DOI: 10.4161/gmic.19625]

23 **Murri M**, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, Queipo-Ortuño MI. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. *BMC Med* 2013; **11**: 46 [PMID: 23433344 DOI: 10.1186/1741-7015-11-46]

24 **Collado MC**, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. *Am J Clin Nutr* 2008; **88**: 894-899 [PMID: 18842773]

25 **Collado MC**, Isolauri E, Laitinen K, Salminen S. Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. *Am J Clin Nutr* 2010; **92**: 1023-1030 [PMID: 20844065 DOI: 10.3945/ajcn.2010.29877]

26 **Kalliomäki M**, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr* 2008; **87**: 534-538 [PMID: 18326589]

27 **Fouhy F**, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. *Gut Microbes* 2012; **3**: 203-220 [PMID: 22572829 DOI: 10.4161/gmic.20169]

28 **Huang HY**, Korivi M, Tsai CH, Yang JH, Tsai YC. Supplementation of Lactobacillus plantarum K68 and Fruit-Vegetable Ferment along with High Fat-Fructose Diet Attenuates Metabolic Syndrome in Rats with Insulin Resistance. *Evid Based Complement Alternat Med* 2013; **2013**: 943020 [PMID: 23690866 DOI: 10.1155/2013/943020]

29 **Park DY**, Ahn YT, Huh CS, McGregor RA, Choi MS. Dual probiotic strains suppress high fructose-induced metabolic syndrome. *World J Gastroenterol* 2013; **19**: 274-283 [PMID: 23345951 DOI: 10.3748/wjg.v19.i2.274]

30 **Kovatcheva-Datchary P**, Arora T. Nutrition, the gut microbiome and the metabolic syndrome. *Best Pract Res Clin Gastroenterol* 2013; **27**: 59-72 [PMID: 23768553 DOI: 10.1016/j.bpg.2013.03.017]

31 **Abrahamsson TR**, Sinkiewicz G, Jakobsson T, Fredrikson M, Björkstén B. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. *J Pediatr Gastroenterol Nutr* 2009; **49**: 349-354 [PMID: 19525871 DOI: 10.1097/MPG.0b013e31818f091b]

32 **Laitinen K**, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. *Br J Nutr* 2009; **101**: 1679-1687 [PMID: 19017418 DOI: 10.1017/s0007114508111461]

33 **Rautava S**, Collado MC, Salminen S, Isolauri E. Probiotics modulate host-microbe interaction in the placenta and fetal gut: a randomized, double-blind, placebo-controlled trial. *Neonatology* 2012; **102**: 178-184 [PMID: 22776980 DOI: 10.1159/000339182]

34 **Ilmonen J**, Isolauri E, Poussa T, Laitinen K. Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. *Clin Nutr* 2011; **30**: 156-164 [PMID: 20970896 DOI: 10.1016/j.clnu.2010.09.009]

35 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**: b2535 [PMID: 19622551 DOI: 10.1136/bmj.b2535]

36 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]

37 **Higgins JPT,** Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). [Updated March 2011]. The Cochrane Collaboration, 2011. Available from: URL: http://handbook.cochrane.org/chapter\_8/8\_assessing\_risk\_of\_bias\_in\_included\_studies.htm

38 **Wells G,** Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Accessed 2013]. Available from: URL: http: //www.ohri.ca/programs/clinical\_epidemiology/oxford.asp

39 **Karlsson Videhult F**, Öhlund I, Stenlund H, Hernell O, West CE. Probiotics during weaning: a follow-up study on effects on body composition and metabolic markers at school age. *Eur J Nutr* 2015; **54**: 355-363 [PMID: 24830782 DOI: 10.1007/s00394-014-0715-y]

40 **Luoto R**, Kalliomäki M, Laitinen K, Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. *Int J Obes* (Lond) 2010; **34**: 1531-1537 [PMID: 20231842 DOI: 10.1038/ijo.2010.50]

41 **Hofman PL**, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, Cutfield WS. Premature birth and later insulin resistance. *N Engl J Med* 2004; **351**: 2179-2186 [PMID: 15548778 DOI: 10.1056/NEJMoa042275]

42 **Longo S**, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). *J Matern Fetal Neonatal Med* 2013; **26**: 222-225 [PMID: 23030765 DOI: 10.3109/14767058.2012.715006]

43 **Crume TL**, Ogden L, West NA, Vehik KS, Scherzinger A, Daniels S, McDuffie R, Bischoff K, Hamman RF, Norris JM, Dabelea D. Association of exposure to diabetes in utero with adiposity and fat distribution in a multiethnic population of youth: the Exploring Perinatal Outcomes among Children (EPOCH) Study. *Diabetologia* 2011; **54**: 87-92 [PMID: 20953862 DOI: 10.1007/s00125-010-1925-3]

44 **Penders J**, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 2006; **118**: 511-521 [PMID: 16882802 DOI: 10.1542/peds.2005-2824]

45 **Million M**, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. *Microb Pathog* 2012; **53**: 100-108 [PMID: 22634320 DOI: 10.1016/j.micpath.2012.05.007]

46 **Million M**, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, Valero R, Raccah D, Vialettes B, Raoult D. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. *Int J Obes* (Lond) 2012; **36**: 817-825 [PMID: 21829158 DOI: 10.1038/ijo.2011.153]

47 **Vendt N**, Grünberg H, Tuure T, Malminiemi O, Wuolijoki E, Tillmann V, Sepp E, Korpela R. Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. *J Hum Nutr Diet* 2006; **19**: 51-58 [PMID: 16448475 DOI: 10.1111/j.1365-277X.2006.00660.x]

48 **Athalye-Jape G**, Deshpande G, Rao S, Patole S. Benefits of probiotics on enteral nutrition in preterm neonates: a systematic review. *Am J Clin Nutr* 2014; **100**: 1508-1519 [PMID: 25411286 DOI: 10.3945/ajcn.114.092551]

49 **Rinne M**, Kalliomäki M, Salminen S, Isolauri E. Probiotic intervention in the first months of life: short-term effects on gastrointestinal symptoms and long-term effects on gut microbiota. *J Pediatr Gastroenterol Nutr* 2006; **43**: 200-205 [PMID: 16877985 DOI: 10.1097/01.mpg.0000228106.91240.5b]

50 **Rautava S**, Luoto R, Salminen S, Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 565-576 [PMID: 22890113 DOI: 10.1038/nrgastro.2012.144]

51 **Franko B**, Vaillant M, Recule C, Vautrin E, Brion JP, Pavese P. Lactobacillus paracasei endocarditis in a consumer of probiotics. *Med Mal Infect* 2013; **43**: 171-173 [PMID: 23622954 DOI: 10.1016/j.medmal.2013.01.007]

52 **Tena D**, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. *Anaerobe* 2014; **27**: 27-30 [PMID: 24657157 DOI: 10.1016/j.anaerobe.2014.03.005]

53 **Tena D**, Martínez NM, Losa C, Fernández C, Medina MJ, Sáez-Nieto JA. Acute acalculous cholecystitis complicated with peritonitis caused by Lactobacillus plantarum. *Diagn Microbiol Infect Dis* 2013; **76**: 510-512 [PMID: 23886436 DOI: 10.1016/j.diagmicrobio.2013.03.018]

54 **Weiss R**. Childhood metabolic syndrome: must we define it to deal with it? *Diabetes Care* 2011; **34** Suppl 2: S171-S176 [PMID: 21525451 DOI: 10.2337/dc11-s214]

**P-Reviewer:** Camacho J, Mentes O, Murdaca G, Tomizawa M **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Table 1 Assessment of risk of bias in the included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study id** | **Random sequence generation** | **Allocation concealment** | **Blinding of participants and personnel** | **Blinding of outcome assessment** | **Incomplete outcome data** | **Selective reporting** | **Other bias** |
| Luoto *et al*[40] | Low | Low | Low | Low | High | Low | Low |
| Videhult  *et al*[39] | Low | Low | Low | Low | High | Low | Low |

**Figure 1 Flow diagram of study selection process.**

